Our new data, together with the previously published studies, expand our knowledge about the benefits of the TG-GSK3β-CUGBP1 pathway in DM1 mouse models, suggesting that GSK3 inhibitors could be effective in DM1 patients of different ages, including pediatric, juvenile and adult patients with DM1. Here, CELF1 is linked to myotonic dystrophy type 1.